Zhejiang Xianju Pharmaceutical Co., Ltd. Class A
SSZSE:0023328.78
CNY
+0.16
(+1.86%)
ISIN
CNE100000K64
Return %
Stock
S&P 500
1Y
-9.02
13.14
3Y
-14.09
80.78
5Y
-14.34
67.74
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Wei Hua Jin
- Full Time Employees
- 3,209
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 1 Xianyao Road Taizhou China 317306
- IPO Date
- Jan 12, 2010
- Website
- xjpharma.com
- Similar Companies
- Business
- Zhejiang Xianju Pharmaceutical Co., Ltd. manufactures and sells a comprehensive range of pharmaceutical products with a specialization in steroidal raw materials and formulations since its founding in 1972. The company's core products include steroids encompassing corticoids and sex hormones with over 100 varieties, along with key pharmaceutical formulations such as rocuronium bromide injection, finasteride tablets, misoprostol tablets, ropivacaine hydrochloride injections, flumazenil injections, prednisolone tablets, dexamethasone sodium phosphate injections, mifepristone tablets, progesterone injections, vecuronium bromide for injections, neostigmine methylsulfate injections, nicardipine hydrochloride injections, and various other steroid drugs and hormone formulations. The firm operates state-of-the-art manufacturing facilities that comply with cGMP, with certifications including FDA inspection and European Certificate of Suitability (CoS) for APIs. Zhejiang Xianju Pharmaceutical also provides a diverse product portfolio including tablets, capsules, injections, creams, gels, and powders. The company has established a strong domestic and international presence, exporting to over 30 countries including markets in Europe, North America, and Southeast Asia, with export revenue comprising around 40% of total sales. Recent major changes include participation in drug consistency evaluations for products such as Ethinylestradiol and Cyproterone Acetate Tablets and dexamethasone acetate tablets, reflecting the company’s commitment to regulatory compliance and product quality enhancement. Zhejiang Xianju Pharmaceutical engages in strategic partnerships, including investment adjustments with Quanxinjili Biotechnology to optimize its biological products segment. The company has increased investment in research and development, focusing on high-value generics and innovative drugs, allocating significant revenue portions to R&D to bolster its product pipeline and expand into therapeutic areas like oncology and cardiovascular treatments. This innovation-driven approach supports its stated mission to become one of the top suppliers of steroid medicines globally while fostering sustainable growth and expanding its international footprint and contract manufacturing services. Headquartered in Zhejiang, China, Zhejiang Xianju Pharmaceutical serves pharmaceutical wholesalers, hospitals, and international distributors. Its operational strategy includes robust supply chain management involving over 300 suppliers worldwide to maintain raw material quality and operational efficiency. The company’s ongoing initiatives emphasize sustainability, expanding product portfolios, and enhancing production capabilities to address evolving market demands in steroids and hormone pharmaceuticals. This detailed and evolving product and service offering positions Zhejiang Xianju Pharmaceutical Co., Ltd. as a leading and innovative entity in the steroid pharmaceutical manufacturing industry with a comprehensive global reach and a focus on compliance, quality, and pharmaceutical innovation.